These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 32198139)

  • 41. PGC1α/CEBPB/CPT1A axis promotes radiation resistance of nasopharyngeal carcinoma through activating fatty acid oxidation.
    Du Q; Tan Z; Shi F; Tang M; Xie L; Zhao L; Li Y; Hu J; Zhou M; Bode A; Luo X; Cao Y
    Cancer Sci; 2019 Jun; 110(6):2050-2062. PubMed ID: 30945396
    [TBL] [Abstract][Full Text] [Related]  

  • 42. ATF3 characterizes aggressive drug-tolerant persister cells in HGSOC.
    Böpple K; Oren Y; Henry WS; Dong M; Weller S; Thiel J; Kleih M; Gaißler A; Zipperer D; Kopp HG; Aylon Y; Oren M; Essmann F; Liang C; Aulitzky WE
    Cell Death Dis; 2024 Apr; 15(4):290. PubMed ID: 38658567
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition.
    Parmar K; Kochupurakkal BS; Lazaro JB; Wang ZC; Palakurthi S; Kirschmeier PT; Yang C; Sambel LA; Färkkilä A; Reznichenko E; Reavis HD; Dunn CE; Zou L; Do KT; Konstantinopoulos PA; Matulonis UA; Liu JF; D'Andrea AD; Shapiro GI
    Clin Cancer Res; 2019 Oct; 25(20):6127-6140. PubMed ID: 31409614
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Identifying off-target effects of etomoxir reveals that carnitine palmitoyltransferase I is essential for cancer cell proliferation independent of β-oxidation.
    Yao CH; Liu GY; Wang R; Moon SH; Gross RW; Patti GJ
    PLoS Biol; 2018 Mar; 16(3):e2003782. PubMed ID: 29596410
    [TBL] [Abstract][Full Text] [Related]  

  • 45. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
    Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
    J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Targeting CPT1A enhances metabolic therapy in human melanoma cells with the BRAF V600E mutation.
    Sung GJ; Choi HK; Kwak S; Song JH; Ko H; Yoon HG; Kang HB; Choi KC
    Int J Biochem Cell Biol; 2016 Dec; 81(Pt A):76-81. PubMed ID: 27793752
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Fatty acid oxidation is associated with proliferation and prognosis in breast and other cancers.
    Aiderus A; Black MA; Dunbier AK
    BMC Cancer; 2018 Aug; 18(1):805. PubMed ID: 30092766
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Lipid catabolism via CPT1 as a therapeutic target for prostate cancer.
    Schlaepfer IR; Rider L; Rodrigues LU; Gijón MA; Pac CT; Romero L; Cimic A; Sirintrapun SJ; Glodé LM; Eckel RH; Cramer SD
    Mol Cancer Ther; 2014 Oct; 13(10):2361-71. PubMed ID: 25122071
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Verticillin A Causes Apoptosis and Reduces Tumor Burden in High-Grade Serous Ovarian Cancer by Inducing DNA Damage.
    Salvi A; Amrine CSM; Austin JR; Kilpatrick K; Russo A; Lantvit D; Calderon-Gierszal E; Mattes Z; Pearce CJ; Grinstaff MW; Colby AH; Oberlies NH; Burdette JE
    Mol Cancer Ther; 2020 Jan; 19(1):89-100. PubMed ID: 31909733
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Collagen Remodeling in the Hypoxic Tumor-Mesothelial Niche Promotes Ovarian Cancer Metastasis.
    Natarajan S; Foreman KM; Soriano MI; Rossen NS; Shehade H; Fregoso DR; Eggold JT; Krishnan V; Dorigo O; Krieg AJ; Heilshorn SC; Sinha S; Fuh KC; Rankin EB
    Cancer Res; 2019 May; 79(9):2271-2284. PubMed ID: 30862717
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Restoration of CPT1A-mediated fatty acid oxidation in mesothelial cells protects against peritoneal fibrosis.
    Su W; Hu Z; Zhong X; Cong A; Zhang Y; Zhou Z; Li J; Su C; Huang Y; Cao W
    Theranostics; 2023; 13(13):4482-4496. PubMed ID: 37649600
    [No Abstract]   [Full Text] [Related]  

  • 52. CircHIPK3/miR-124 affects angiogenesis in early-onset preeclampsia via CPT1A-mediated fatty acid oxidation.
    Wu Y; Huang J; Liu L; Zhang X; Zhang W; Li Q
    J Mol Med (Berl); 2024 Aug; 102(8):1037-1049. PubMed ID: 38904677
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Inhibition of palmitoyltransferase ZDHHC12 sensitizes ovarian cancer cells to cisplatin through ROS-mediated mechanisms.
    Zhang X; Liao X; Wang M; Liu J; Han J; An D; Zheng T; Wang X; Cheng H; Liu P
    Cancer Sci; 2024 Apr; 115(4):1170-1183. PubMed ID: 38287874
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Phyllanthusmin Derivatives Induce Apoptosis and Reduce Tumor Burden in High-Grade Serous Ovarian Cancer by Late-Stage Autophagy Inhibition.
    Young AN; Herrera D; Huntsman AC; Korkmaz MA; Lantvit DD; Mazumder S; Kolli S; Coss CC; King S; Wang H; Swanson SM; Kinghorn AD; Zhang X; Phelps MA; Aldrich LN; Fuchs JR; Burdette JE
    Mol Cancer Ther; 2018 Oct; 17(10):2123-2135. PubMed ID: 30018048
    [TBL] [Abstract][Full Text] [Related]  

  • 55. CBX2 identified as driver of anoikis escape and dissemination in high grade serous ovarian cancer.
    Wheeler LJ; Watson ZL; Qamar L; Yamamoto TM; Post MD; Berning AA; Spillman MA; Behbakht K; Bitler BG
    Oncogenesis; 2018 Nov; 7(11):92. PubMed ID: 30478317
    [TBL] [Abstract][Full Text] [Related]  

  • 56. MicroRNA-625-3p improved proliferation and involved chemotherapy resistance via targeting PTEN in high grade ovarian serous carcinoma.
    Zhong L; Liu X; Wang L; Liu Y; Zhang D; Zhao Y
    J Ovarian Res; 2022 Jan; 15(1):7. PubMed ID: 35027053
    [TBL] [Abstract][Full Text] [Related]  

  • 57. DIO3, the thyroid hormone inactivating enzyme, promotes tumorigenesis and metabolic reprogramming in high grade serous ovarian cancer.
    Moskovich D; Alfandari A; Finkelshtein Y; Weisz A; Katzav A; Kidron D; Edelstein E; Veroslavski D; Perets R; Arbib N; Kadan Y; Fishman A; Lerer B; Ellis M; Ashur-Fabian O
    Cancer Lett; 2021 Mar; 501():224-233. PubMed ID: 33221455
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Epigenetic Reprogramming Strategies to Reverse Global Loss of 5-Hydroxymethylcytosine, a Prognostic Factor for Poor Survival in High-grade Serous Ovarian Cancer.
    Tucker DW; Getchell CR; McCarthy ET; Ohman AW; Sasamoto N; Xu S; Ko JY; Gupta M; Shafrir A; Medina JE; Lee JJ; MacDonald LA; Malik A; Hasselblatt KT; Li W; Zhang H; Kaplan SJ; Murphy GF; Hirsch MS; Liu JF; Matulonis UA; Terry KL; Lian CG; Dinulescu DM
    Clin Cancer Res; 2018 Mar; 24(6):1389-1401. PubMed ID: 29263182
    [No Abstract]   [Full Text] [Related]  

  • 59. HCK Promotes High-Grade Serous Ovarian Cancer Tumorigenesis through CD44 and NOTCH3 Signaling.
    Khella CA; Franciosa L; Rodirguez-Rodriguez L; Rajkarnikar R; Mythreye K; Gatza ML
    Mol Cancer Res; 2023 Oct; 21(10):1037-1049. PubMed ID: 37342066
    [TBL] [Abstract][Full Text] [Related]  

  • 60. TRAF4 promotes the malignant progression of high-grade serous ovarian cancer by activating YAP pathway.
    Luo X; Cao J; Zhang C; Huang H; Liu J
    Biochem Biophys Res Commun; 2022 Oct; 627():68-75. PubMed ID: 36029535
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.